Literature DB >> 6281741

Metabolic and distribution studies with radiolabeled 5-fluorouracil.

D Young, E Vine, A Ghanbarpour, J Shani, J K Siemsen, W Wolf.   

Abstract

5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma. We synthesized 5-FU with trace amounts of 18F-5-FU and administered the compounds intravenously to 6 cancer patients. The patients were scanned at 2 hr intervals for 12 hrs and their urine collected whenever possible. We also injected 5-FU with the tracer 18F-5-FU, at pharmacological doses, into non-tumored rats, and sampled their bile and blood for 95 mins post-injection. For comparison, 2-14C-5-FU was injected into non-tumored rats and their bile and blood sampled at the same intervals. Minute quantities of rat bile and serum were analyzed chromatographically by high-performance TLC. 5-FU and two of its metabolites (FBAL and FUPA) were identified and quantified by this technique. Both percentage and absolute amounts of 5-FU in the bile follow comparative kinetic patterns. While the liver and the urinary bladder were clearly observable in all 16 patients, the detectability of the gall-bladder was correlated to the inverse of the alkaline phosphatase level in the blood. This work suggests that the diversity of the 5-FU metabolism in cancer patients may allow the use of 18F-5-FU as a probe for understanding those individual variabilities in clinical situations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281741

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  4 in total

Review 1.  The unique potential for noninvasive imaging in modernizing drug development and in transforming therapeutics: PET/MRI/MRS.

Authors:  Walter Wolf
Journal:  Pharm Res       Date:  2010-10-01       Impact factor: 4.200

Review 2.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

3.  An optimized synthesis of 18F-labelled 5-fluorouracil and a reevaluation of its use as a prognostic agent.

Authors:  G W Visser; G C Gorree; B J Braakhuis; J D Herscheid
Journal:  Eur J Nucl Med       Date:  1989

Review 4.  Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.

Authors:  P Chrisp; D McTavish
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.